(Total Views: 350)
Posted On: 01/24/2022 8:51:00 AM
Post# of 1418
I love it when a plan comes together...
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients - January 24, 2022 8:34am EST
New York, NY, and Tel Aviv, ISRAEL, Jan. 24, 2022 (GLOBE NEWSWIRE) -- § Clinical Data Will be Released Thursday, January 27th, 2022
via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease theragnostic joint venture partner NLC Pharma Ltd., today announced a data lock for the interim data analysis for the Company’s Tollovir™ Phase 2 Clinical Trial for the treatment of hospitalized (severe/critical) COVID-19 patients. The Company will release the results on Thursday, January 27th, 2022.
“We are very excited to see the first controlled clinical trial data for Tollovir,” said Dr. Dorit Arad, Founder & Chief Scientific Officer of NLC Pharma, Todos Medical’s 3CL protease biology theragnostics joint venture partner. “We are also looking forward to completing the formation of 3CL Sciences to advance this critically important science into medical use.”
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
https://investor.todosmedical.com/news-events...ir-phase-2
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients - January 24, 2022 8:34am EST
New York, NY, and Tel Aviv, ISRAEL, Jan. 24, 2022 (GLOBE NEWSWIRE) -- § Clinical Data Will be Released Thursday, January 27th, 2022
via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease theragnostic joint venture partner NLC Pharma Ltd., today announced a data lock for the interim data analysis for the Company’s Tollovir™ Phase 2 Clinical Trial for the treatment of hospitalized (severe/critical) COVID-19 patients. The Company will release the results on Thursday, January 27th, 2022.
“We are very excited to see the first controlled clinical trial data for Tollovir,” said Dr. Dorit Arad, Founder & Chief Scientific Officer of NLC Pharma, Todos Medical’s 3CL protease biology theragnostics joint venture partner. “We are also looking forward to completing the formation of 3CL Sciences to advance this critically important science into medical use.”
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
https://investor.todosmedical.com/news-events...ir-phase-2
(0)
(0)
